Development of therapeutic antibodies for the treatment of diseases
It has been more than three decades since the first monoclonal antibody was approved by
the United States Food and Drug Administration (US FDA) in 1986, and during this time …
the United States Food and Drug Administration (US FDA) in 1986, and during this time …
The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing
Following the discovery of T helper 17 (TH17) cells, the past decade has witnessed a major
revision of the TH subset paradigm and substantial progress has been made in deciphering …
revision of the TH subset paradigm and substantial progress has been made in deciphering …
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …
population. This guideline addresses important clinical questions that arise in psoriasis …
Immunology of psoriasis
The skin is the front line of defense against insult and injury and contains many epidermal
and immune elements that comprise the skin-associated lymphoid tissue (SALT). The …
and immune elements that comprise the skin-associated lymphoid tissue (SALT). The …
Vascular inflammation and oxidative stress: major triggers for cardiovascular disease
Cardiovascular disease is a leading cause of death and reduced quality of life, proven by
the latest data of the Global Burden of Disease Study, and is only gaining in prevalence …
the latest data of the Global Burden of Disease Study, and is only gaining in prevalence …
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis
E Sbidian, A Chaimani, R Guelimi… - Cochrane Database …, 2023 - cochranelibrary.com
Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …
manifestations, or both, and it has a major impact on quality of life. Although there is …
Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
Background Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of
treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to …
treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to …
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled …
IB McInnes, PJ Mease, B Kirkham, A Kavanaugh… - The Lancet, 2015 - thelancet.com
Background Interleukin 17A is a proinflammatory cytokine that is implicated in the
pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous …
pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous …
Targeting IL-17 and TH17 cells in chronic inflammation
P Miossec, JK Kolls - Nature reviews Drug discovery, 2012 - nature.com
The key role of interleukin-17 (IL-17) and T helper 17 (TH17) cells in tissue inflammation,
autoimmunity and host defence led to the experimental targeting of these molecules in …
autoimmunity and host defence led to the experimental targeting of these molecules in …
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
Abstract The cytokine interleukin-12 (IL-12) was thought to have a central role in T cell–
mediated responses in inflammation for more than a decade after it was first identified …
mediated responses in inflammation for more than a decade after it was first identified …